Madecassoside

Catalog No.S3843 Synonyms: Asiaticoside A

For research use only.

Madecassoside (Asiaticoside A) is the main active triterpene constituent of Centella asiatica herbs, a traditional Chinese medicine for wound healing and scar management.

Madecassoside Chemical Structure

CAS No. 34540-22-2

Selleck's Madecassoside has been cited by 1 Publication

Purity & Quality Control

Related Other Products

Biological Activity

Description Madecassoside (Asiaticoside A) is the main active triterpene constituent of Centella asiatica herbs, a traditional Chinese medicine for wound healing and scar management.
In vitro

Madecassoside (10, 30, 100 μmol/L) could reverse morphological changes, elevate cell viability, increase glutathione levels, and decrease lactate dehydrogenase andmalondialdehyde levels caused by H2O2 in a concentration-dependent manner. It attenuates apoptosis, preventing the activation of caspase-3 and the loss of mitochondria membrane potential, as well as the phosphorylation of p38 mitogen activated protein kinase (MAPK) in HUVECs. Hence, Madecassoside could protect HUVECs against lipid peroxidation and apoptosis caused by H2O2[1].

In vivo The pharmacokinetic study of madecassoside in rats indicates that the maximum plasma concentration is 303.75 ± 28.53 ng/mL after single oral administration (100 mg/kg). Madecassoside, administered orally for 20 days at doses of 6, 12, and 24 mg/kg, effectively facilitates burn wound healing in mice. It could reduce the burn wound area, leading to a better healing pattern with almost complete wound closure in mice[1]. Madecassoside has potent anti-pulmonary fibrosis (PF) effects when administered p.o., despite having extremely low oral bioavailability. The potent anti-PF effects induced by p.o. madecassoside in mice are not mediated by its metabolites or itself after absorption into blood. i.p. madecassoside has no anti-PF effect. Madecassoside increases the activity of PPAR-γ, which subsequently increases HGF expression in colonic epithelial cells. HGF then enters into the circulation and lung tissue to exert an anti-PF effect[2].

Protocol (from reference)

Cell Research:

[1]

  • Cell lines: human umbilical vein endothelial cells (HUVECs)
  • Concentrations: 10, 30, 100 μmol/L
  • Incubation Time: 8 h
  • Method:

    HUVECs are harvested using 0.25% trypsin solution and inoculated in 96-well plates at a density of 1 × 104 cells/well. Cells are treated with H2O2 (500 μmol/L) and/or a variety of concentrations of madecassoside (10, 30, 100 μmol/L). The culture plate is then placed in 5% (v/v) CO2 at 37◦C for 8 h. At the end of incubation, 20 μL of MTT (5 mg/mL) is added to each well and the cells are incubated for another 4 h at 37◦C with 5% CO2. The supernatants are then discarded, and 200 μL of DMSO is added to each well. The absorbance is read at 540 nm and cell viability is expressed as percentage of untreated cells.

  • (Only for Reference)
Animal Research:

[2]

  • Animal Models: Female ICR mice, 6-8 weeks-old and weighing 22-26 g
  • Dosages: 40 mg/kg
  • Administration: p.o. or i.p.
  • (Only for Reference)

Solubility (25°C)

In vitro

DMSO 100 mg/mL
(102.55 mM)
Water 100 mg/mL
(102.55 mM)
Ethanol 100 mg/mL
(102.55 mM)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 975.12
Formula

C48H78O20

CAS No. 34540-22-2
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1CCC2(CCC3(C(=CCC4C3(CC(C5C4(CC(C(C5(C)CO)O)O)C)O)C)C2C1C)C)C(=O)OC6C(C(C(C(O6)COC7C(C(C(C(O7)CO)OC8C(C(C(C(O8)C)O)O)O)O)O)O)O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02353273 Completed Drug: WH-1 ointment Diabetic Foot Oneness Biotech Co. Ltd. July 22 2015 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Madecassoside | Madecassoside supplier | purchase Madecassoside | Madecassoside cost | Madecassoside manufacturer | order Madecassoside | Madecassoside distributor